CClinicalTrials.gg
Sign In
RecruitingNCT07198074Updated Sep 29, 2026

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

A Phase 3 interventional study of Bevacizumab and Biospecimen Collection in Advanced Endometrial Carcinoma and Recurrent Endometrial Carcinoma, sponsored by National Cancer Institute (NCI). Recruiting at 294 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To demonstrate that bevacizumab, an anti-VEGF antibody therapy, (or an anti-VEGF antibody biosimilar) in combination with carboplatin, paclitaxel, and pembrolizumab is superior to carboplatin, paclitaxel, and pembrolizumab (the control arm) or carboplatin, paclitaxel, and bevacizumab in prolonging progression-free survival (PFS) in patients with pMMR, TP53 mutated advanced stage (III or IV) or recurrent endometrial cancer.

SECONDARY OBJECTIVES:

I. To demonstrate that bevacizumab in combination with carboplatin, paclitaxel, and pembrolizumab is superior to carboplatin, paclitaxel, and pembrolizumab or carboplatin, paclitaxel, and bevacizumab in prolonging overall survival (OS) in patients with pMMR, TP53 mutated advanced stage (III or IV) or recurrent endometrial cancer.

II. To examine the impact of the addition of bevacizumab in combination with carboplatin and paclitaxel or with carboplatin, paclitaxel, and pembrolizumab on PFS and OS based on type of p53 immunohistochemistry (IHC) aberrancy (over expression/cytoplasmic expression versus null [complete absence of staining]) and mutation type.

III. To evaluate toxicity on treatment with bevacizumab when combined with carboplatin, paclitaxel, and/or pembrolizumab as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.)5.0.

IV. To explore the anti-tumor activity in each treatment arm as assessed by objective response rate in the subset of patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM 1 (REFERENCE ARM): Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to an additional14 cycles. Additionally, patients undergo urine and blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.

ARM 2 (EXPERIMENTAL TRIPLET ARM): Patients receive paclitaxel IV over 3 hours, carboplatin IV, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

ARM 3 (EXPERIMENTAL QUADRUPLET ARM): Patients receive paclitaxel IV over 3 hours, carboplatin IV, pembrolizumab IV over 30 minutes, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes every 6 weeks for up to an additional 14 cycles and bevacizumab IV every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

After completion of study treatment, patients are followed every 3 months for 2 years then every 6 months for up to 3 years.

02

Conditions studied

  • Advanced Endometrial Carcinoma
  • Recurrent Endometrial Carcinoma
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Documentation of disease:

    • Stage III and stage IVA endometrial cancers (with measurable disease),
    • Stage IVB endometrial cancer (with or without measurable disease), or
    • Recurrent endometrial cancer (with or without measurable disease)
  • In patients with measurable disease, lesions will be defined and monitored by RECIST 1.1. Measurable disease (RECIST 1.1) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT or MRI. Lymph nodes must be ≥ 15 mm in short axis when measured by CT or MRI
  • Histologic confirmation of the original primary tumor is required (submission of pathology report[s] is required). Patients with the following histologic types are eligible: endometrioid, serous, dedifferentiated/undifferentiated, clear cell, mixed epithelial, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.)

  • Patients must have:

    • Tumoral mismatch repair proficient (pMMR) disease as assessed by immunohistochemistry (IHC) AND
    • P53 IHC with aberrant staining pattern (aberrant p53 expression is consistent with mutant TP53). TP53 mutation by next-generation sequencing will also be accepted
  • A pathology report demonstrating results of institutional MMR IHC and p53 IHC and/or TP53 by next-generation sequencing

  • Patients may have received:

    • NO prior chemotherapy for treatment of endometrial cancer OR
    • Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed ≥ 12 months prior to registration
  • Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration. For patients with recent radiation, they must have RECIST-evaluable disease outside of the radiation field and have recovered their marrow function
  • Patients may have received prior hormonal (endocrine) therapy. All hormonal (endocrine) therapy must have been completed at least 1 week prior to registration
  • NO prior pembrolizumab (or other anti-PD1, anti-PDL1 or anti-CTLA4 therapy) or bevacizumab (or other antiangiogenic therapy)
  • Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of disease progression. Patients with brain metastases must have follow up imaging demonstrating no evidence of disease progression and that the disease is stable off of steroids
  • Age ≥ 18
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Not pregnant and not nursing
  • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3
  • Platelets ≥ 100,000 cells/mm\^3
  • Hemoglobin ≥ 8 g/dl
  • Creatinine clearance (CrCl) of ≥ 30 mL/min by the Cockcroft-Gault formula
  • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
  • No active infection requiring parenteral antibiotics
  • No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube
  • No clinically significant bleeding within 28 days prior to registration
  • No uncontrolled hypertension, defined as systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg
  • No major surgery within 28 days of initiation of bevacizumab

  • No active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease

    • Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
    • Topical or inhaled steroids are allowed
    • Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), and anti-thyroid antibodies should be evaluated with the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
  • No history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
  • No history of stem cell or solid organ transplant
  • No history of allergic reaction to the study agent(s) or compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients)
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
255 participants (estimated)

Study arms

  • Active comparator
    Arm 1 (paclitaxel, carboplatin, pembrolizumab)

    Patients receive paclitaxel IV over 3 hours, carboplatin IV and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to an additional 14 cycles. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

    Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Paclitaxel · Biological: Pembrolizumab

  • Experimental
    Arm 2 (paclitaxel, carboplatin, bevacizumab)

    Patients receive paclitaxel IV over 3 hours, carboplatin IV, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

    Biological: Bevacizumab · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Paclitaxel

  • Experimental
    Arm 3 (paclitaxel, carboplatin, pembrolizumab, bevacizumab)

    Patients receive paclitaxel IV over 3 hours, carboplatin IV, pembrolizumab IV over 30 minutes, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes every 6 weeks for up to an additional 14 cycles and bevacizumab IV every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

    Biological: Bevacizumab · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Paclitaxel · Biological: Pembrolizumab

Interventions

  • BiologicalBevacizumab

    Given IV

    Also known as: ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avegra, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-aveg, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-byva, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-nwgd, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, Byvasda, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, IBI 305, IBI-305, IBI305, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Jobevne, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev

  • ProcedureBiospecimen Collection

    Undergo urine and blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • DrugCarboplatin

    Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • DrugPaclitaxel

    Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • BiologicalPembrolizumab

    Given IV

    Also known as: BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475

05

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Will be defined using Response Evaluation Criteria in Solid Tumors version (v) 1.1. Will be tested using one-sided log-rank tests with α-levels stratified by factors used in the randomization. Patients will be grouped by their randomized treatment assignment for intention-to-treat (ITT) analyses, supported by patients in ITT population. Treatment hazard ratios and their 95% confidence intervals will be estimated using a Cox proportional hazards models specified with a main effect for the randomized treatment assignment and stratified using the stratification factors applied at randomization.

    Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Secondary outcomes

  1. Overall survival (OS)

    Will be assessed with proportional hazards modeling stratified for stratification factors at baseline. Hazard ratios and corresponding 2-sided 95% confidence intervals will be estimated for treatment (with Arm 1 as the reference arm).

    Time frame: From study entry to time of death from any cause, assessed up to 5 years

  2. Prognostic and predictive associations of type of TP53 mutation status with PFS

    Will be assessed with proportional hazards modeling stratified for stratification factors at baseline and adjusted by randomized treatment arm assignment. Hazard ratios and corresponding 2-sided 95% confidence intervals will be estimated for TP53 status as well as treatment hazard ratios (with Arm 1 as the reference arm) within TP53 subgroups.

    Time frame: Up to 5 years

  3. Prognostic and predictive associations of type of TP53 mutation status with OS

    Will be assessed with proportional hazards modeling stratified for stratification factors at baseline and adjusted by randomized treatment arm assignment. Hazard ratios and corresponding 2-sided 95% confidence intervals will be estimated for TP53 status as well as treatment hazard ratios (with Arm 1 as the reference arm) within TP53 subgroups.

    Time frame: Up to 5 years

  4. Incidence of adverse events (AEs) in treatment with bevacizumab when combined with carboplatin, paclitaxel, and pembrolizumab

    The nature, frequency, and degree of toxicity will be tabulated at the system organ class and AE-specific term levels using Common Terminology Criteria for Adverse Events v 5.0. Each patient will be represented according to maximum grade observed for each term. Tabulations will show the number and percentage of patients by maximum grade, within the treatment group received, regardless of the randomized treatment assignment. No specific hypothesis test is pre-specified.

    Time frame: Up to 90 days after last dose of study treatment

  5. Objective response rate

    Will be defined as the binomial proportion of evaluable patients with a best overall response of complete response or partial response. Will be supported by their 2-sided, 95% Wilson-Score confidence intervals. The relative odds of response in each experimental group (vs the reference group) will be estimated using a multivariable logistic regression model specified with main effects for the treatment groups and stratified by the stratification factors reported at baseline.

    Time frame: Within 12 months of initiating therapy

Other outcomes

  1. PFS

    Will estimate the PFS treatment effect and the corresponding 95% confidence intervals by sex.

    Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

  2. PFS

    Will estimate the PFS treatment effect and the corresponding 95% confidence intervals by race.

    Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

  3. PFS

    Will estimate the PFS treatment effect and the corresponding 95% confidence intervals by ethnicity.

    Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

06

Study locations

292 of 294 sites recruiting
  • University of Alabama at Birmingham Cancer Center
    Birmingham, Alabama 35233, United States
    Recruiting
  • Alaska Women's Cancer Care
    Anchorage, Alaska 99508, United States
    Recruiting
  • Cancer Center at Saint Joseph's
    Phoenix, Arizona 85004, United States
    Recruiting
  • Banner University Medical Center - Tucson
    Tucson, Arizona 85719, United States
    Recruiting
  • University of Arizona Cancer Center-North Campus
    Tucson, Arizona 85719, United States
    Recruiting
  • Highlands Oncology Group - Fayetteville
    Fayetteville, Arkansas 72703, United States
    • Site Public Contact · Contact · research@hogonc.com · 479-872-8100
    • Joseph T. Beck · Principal investigator
    Recruiting
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
    • Site Public Contact · Contact · 501-686-8274
    • Heather R. Williams · Principal investigator
    Recruiting
  • Highlands Oncology Group - Rogers
    Rogers, Arkansas 72758, United States
    • Site Public Contact · Contact · research@hogonc.com · 479-872-8130
    • Joseph T. Beck · Principal investigator
    Recruiting
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
    • Site Public Contact · Contact · research@hogonc.com · 479-872-8130
    • Joseph T. Beck · Principal investigator
    Recruiting
  • Mercy Cancer Center - Carmichael
    Carmichael, California 95608, United States
    Recruiting
  • Mercy San Juan Medical Center
    Carmichael, California 95608, United States
    Recruiting
  • Kaiser Permanente Dublin
    Dublin, California 94568, United States
    • Site Public Contact · Contact · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Mercy Cancer Center - Elk Grove
    Elk Grove, California 95758, United States
    Recruiting
  • Kaiser Permanente-Fremont
    Fremont, California 94538, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente Fresno Orchard Plaza
    Fresno, California 93720, United States
    • Site Public Contact · Contact · 833-574-2273
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Los Angeles General Medical Center
    Los Angeles, California 90033, United States
    Recruiting
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    • Site Public Contact · Contact · 323-865-0451
    • Koji Matsuo · Principal investigator
    Recruiting
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
    Recruiting
  • Kaiser Permanente- Modesto MOB II
    Modesto, California 95356, United States
    • Site Public Contact · Contact · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente-Oakland
    Oakland, California 94611, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Stanford Cancer Institute Palo Alto
    Palo Alto, California 94304, United States
    Recruiting
  • Eisenhower Medical Center
    Rancho Mirage, California 92270, United States
    • Site Public Contact · Contact · 760-834-3798
    • Mark Genesen · Principal investigator
    Recruiting
  • Mercy Cancer Center - Rocklin
    Rocklin, California 95765, United States
    Recruiting
  • Kaiser Permanente-Roseville
    Roseville, California 95661, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente Downtown Commons
    Sacramento, California 95814, United States
    • Site Public Contact · Contact · kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Mercy Cancer Center - Sacramento
    Sacramento, California 95816, United States
    Recruiting
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
    • Site Public Contact · Contact · 916-734-3089
    • Nancy T. Nguyen · Principal investigator
    Recruiting
  • Kaiser Permanente-South Sacramento
    Sacramento, California 95823, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente-San Francisco
    San Francisco, California 94115, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente-Santa Teresa-San Jose
    San Jose, California 95119, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente San Leandro
    San Leandro, California 94577, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser San Rafael-Gallinas
    San Rafael, California 94903, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente Medical Center - Santa Clara
    Santa Clara, California 95051, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente-Santa Rosa
    Santa Rosa, California 95403, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente-South San Francisco
    South San Francisco, California 94080, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente-Vallejo
    Vallejo, California 94589, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kaiser Permanente-Walnut Creek
    Walnut Creek, California 94596, United States
    • Site Public Contact · Contact · Kpoct@kp.org · 877-642-4691
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Woodland Memorial Hospital
    Woodland, California 95695, United States
    Recruiting
  • UCHealth University of Colorado Hospital
    Aurora, Colorado 80045, United States
    • Site Public Contact · Contact · 720-848-0650
    • Bradley R. Corr · Principal investigator
    Recruiting
  • UCHealth Memorial Hospital Central
    Colorado Springs, Colorado 80909, United States
    • Site Public Contact · Contact · 719-365-2406
    • Bradley R. Corr · Principal investigator
    Recruiting
  • Memorial Hospital North
    Colorado Springs, Colorado 80920, United States
    • Site Public Contact · Contact · 719-364-6700
    • Bradley R. Corr · Principal investigator
    Recruiting
  • Poudre Valley Hospital
    Fort Collins, Colorado 80524, United States
    • Site Public Contact · Contact · 970-297-6150
    • Bradley R. Corr · Principal investigator
    Recruiting
  • Cancer Care and Hematology-Fort Collins
    Fort Collins, Colorado 80528, United States
    • Site Public Contact · Contact · Roster@nrgoncology.org · 412-339-5294
    • Bradley R. Corr · Principal investigator
    Recruiting
  • UCHealth Greeley Hospital
    Greeley, Colorado 80631, United States
    • Site Public Contact · Contact · Roster@nrgoncology.org · 412-339-5294
    • Bradley R. Corr · Principal investigator
    Recruiting
  • UCHealth Highlands Ranch Hospital
    Highlands Ranch, Colorado 80129, United States
    • Site Public Contact · Contact · 720-848-0650
    • Bradley R. Corr · Principal investigator
    Recruiting
  • Medical Center of the Rockies
    Loveland, Colorado 80538, United States
    • Site Public Contact · Contact · 970-203-7083
    • Bradley R. Corr · Principal investigator
    Recruiting
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
    • Site Public Contact · Contact · 860-545-5363
    • Amy K. Brown · Principal investigator
    Recruiting
  • Hartford HealthCare - Manchester
    Manchester, Connecticut 06042, United States
    • Site Public Contact · Contact · 860-972-4700
    • Amy K. Brown · Principal investigator
    Recruiting
  • The Hospital of Central Connecticut
    New Britain, Connecticut 06050, United States
    • Site Public Contact · Contact · 860-224-5660
    • Amy K. Brown · Principal investigator
    Recruiting
  • Beebe South Coastal Health Campus
    Millville, Delaware 19967, United States
    Recruiting
  • Helen F Graham Cancer Center
    Newark, Delaware 19713, United States
    Recruiting
  • Medical Oncology Hematology Consultants PA
    Newark, Delaware 19713, United States
    Recruiting
  • Beebe Health Campus
    Rehoboth Beach, Delaware 19971, United States
    Recruiting
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    • Site Public Contact · Contact · 202-877-8839
    • Ebony R. Hoskins · Principal investigator
    Recruiting
  • Sarasota Memorial Hospital-Venice
    N. Venice, Florida 34275, United States
    • Site Public Contact · Contact · 941-261-9000
    • Toni P. Kilts · Principal investigator
    Recruiting
  • Florida Cancer Specialists - Sarasota Downtown
    Sarasota, Florida 34239, United States
    Recruiting
  • FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery
    Sarasota, Florida 34239, United States
    Recruiting
  • Sarasota Memorial Hospital
    Sarasota, Florida 34239, United States
    • Site Public Contact · Contact · 941-917-2225
    • Toni P. Kilts · Principal investigator
    Recruiting
  • Sarasota Memorial Health Care Center at University Parkway
    Sarasota, Florida 34243, United States
    • Site Public Contact · Contact · 941-917-6519
    • Toni P. Kilts · Principal investigator
    Recruiting
  • Florida Cancer Specialists - Venice Pinebrook
    Venice, Florida 34275, United States
    Recruiting
  • Grady Health System
    Atlanta, Georgia 30303, United States
    • Site Public Contact · Contact · 404-778-1868
    • Kristen Starbuck · Principal investigator
    Recruiting
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
    • Site Public Contact · Contact · 888-946-7447
    • Kristen Starbuck · Principal investigator
    Recruiting
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    • Site Public Contact · Contact · 404-778-1868
    • Kristen Starbuck · Principal investigator
    Recruiting
  • Augusta University Medical Center
    Augusta, Georgia 30912, United States
    • Site Public Contact · Contact · ga_cares@augusta.edu · 706-721-2388
    • Bunja J. Rungruang · Principal investigator
    Recruiting
  • Emory Decatur Hospital
    Decatur, Georgia 30033, United States
    Recruiting
  • Kaiser Permanente Moanalua Medical Center
    Honolulu, Hawaii 96819, United States
    • Site Public Contact · Contact · shelley.a.clark@kp.org · 808-432-5195
    • Juraj Kavecansky · Principal investigator
    Recruiting
  • Kootenai Health - Coeur d'Alene
    Coeur d'Alene, Idaho 83814, United States
    • Site Public Contact · Contact · mccinfo@mtcancer.org · 406-969-6060
    • John M. Schallenkamp · Principal investigator
    Recruiting
  • Kootenai Clinic Cancer Services - Post Falls
    Post Falls, Idaho 83854, United States
    • Site Public Contact · Contact · mccinfo@mtcancer.org · 406-969-6060
    • John M. Schallenkamp · Principal investigator
    Recruiting
  • Kootenai Clinic Cancer Services - Sandpoint
    Sandpoint, Idaho 83864, United States
    • Site Public Contact · Contact · mccinfo@mtcancer.org · 406-969-6060
    • John M. Schallenkamp · Principal investigator
    Recruiting
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • Rush MD Anderson Cancer Center
    Chicago, Illinois 60612, United States
    • Site Public Contact · Contact · Cancer_Studies@rush.edu · 312-226-2371
    • Alexander C. Cohen · Principal investigator
    Recruiting
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
    Recruiting
  • Carle at The Riverfront
    Danville, Illinois 61832, United States
    • Site Public Contact · Contact · Research@Carle.com · 800-446-5532
    • Pratima Chalasani · Principal investigator
    Recruiting
  • Cancer Care Specialists of Illinois - Decatur
    Decatur, Illinois 62526, United States
    Recruiting
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
    Recruiting
  • Northwestern Medicine Cancer Center Kishwaukee
    DeKalb, Illinois 60115, United States
    • Site Public Contact · Contact · Donald.Smith3@nm.org · 630-352-5360
    • Emma Barber · Principal investigator
    Recruiting
  • Carle Physician Group-Effingham
    Effingham, Illinois 62401, United States
    • Site Public Contact · Contact · Research@carle.com · 800-446-5532
    • Pratima Chalasani · Principal investigator
    Recruiting
  • NorthShore University HealthSystem-Evanston Hospital
    Evanston, Illinois 60201, United States
    • Site Public Contact · Contact · 847-570-2109
    • Mary T. Jenkins Vogel · Principal investigator
    Recruiting
  • Northwestern Medicine Cancer Center Delnor
    Geneva, Illinois 60134, United States
    • Site Public Contact · Contact · Donald.Smith3@nm.org · 630-352-5360
    • Emma Barber · Principal investigator
    Recruiting
  • NorthShore University HealthSystem-Glenbrook Hospital
    Glenview, Illinois 60026, United States
    • Site Public Contact · Contact · 847-570-2109
    • Mary T. Jenkins Vogel · Principal investigator
    Recruiting
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
    Recruiting
  • NorthShore University HealthSystem-Highland Park Hospital
    Highland Park, Illinois 60035, United States
    • Site Public Contact · Contact · 847-570-2109
    • Mary T. Jenkins Vogel · Principal investigator
    Recruiting
  • Carle Physician Group-Mattoon/Charleston
    Mattoon, Illinois 61938, United States
    • Site Public Contact · Contact · Research@carle.com · 800-446-5532
    • Pratima Chalasani · Principal investigator
    Recruiting
  • UC Comprehensive Cancer Center at Silver Cross
    New Lenox, Illinois 60451, United States
    Recruiting
  • Carle BroMenn Medical Center
    Normal, Illinois 61761, United States
    • Site Public Contact · Contact · Research@Carle.com · 800-446-5532
    • Pratima Chalasani · Principal investigator
    Recruiting
  • Carle Cancer Institute Normal
    Normal, Illinois 61761, United States
    • Site Public Contact · Contact · Research@Carle.com · 800-446-5532
    • Pratima Chalasani · Principal investigator
    Recruiting
  • Cancer Care Center of O'Fallon
    O'Fallon, Illinois 62269, United States
    Recruiting
  • HSHS Saint Elizabeth's Hospital
    O'Fallon, Illinois 62269, United States
    Recruiting
  • Northwestern Medicine Oak Brook
    Oak Brook, Illinois 60523, United States
    Recruiting
  • Rush MD Anderson Cancer Center at Rush Oak Park
    Oak Park, Illinois 60304, United States
    • Site Public Contact · Contact · Cancer_Studies@rush.edu · 312-226-2371
    • Alexander C. Cohen · Principal investigator
    Recruiting
  • Northwestern Medicine Orland Park
    Orland Park, Illinois 60462, United States
    Recruiting
  • University of Chicago Medicine-Orland Park
    Orland Park, Illinois 60462, United States
    Recruiting
  • OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
    Recruiting
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
    • Site Public Contact · Contact · 217-545-7929
    • Bryan A. Faller · Principal investigator
    Recruiting
  • Springfield Clinic
    Springfield, Illinois 62702, United States
    • Site Public Contact · Contact · 800-444-7541
    • Bryan A. Faller · Principal investigator
    Recruiting
  • Springfield Memorial Hospital
    Springfield, Illinois 62781, United States
    Recruiting
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
    • Site Public Contact · Contact · Research@carle.com · 800-446-5532
    • Pratima Chalasani · Principal investigator
    Recruiting
  • Northwestern Medicine Cancer Center Warrenville
    Warrenville, Illinois 60555, United States
    • Site Public Contact · Contact · Donald.Smith3@nm.org · 630-352-5360
    • Emma Barber · Principal investigator
    Recruiting
  • UChicago Medicine Northwest Indiana
    Crown Point, Indiana 46307, United States
    Recruiting
  • Goshen Center for Cancer Care
    Goshen, Indiana 46526, United States
    Recruiting

Showing the first 100 of 294 sites.

07

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07198074
Lead sponsor
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Jan 27, 2026
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Amanda N Fader
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Endometrial Neoplasms→

Other studies from this sponsor

National Cancer Institute (NCI)

Start the discussion